ACSS2 and metabolic disease: In summary, our discovery of the isoxazole ACS inhibitors and the structural and biochemical characterization of their mechanism of inhibition provides novel provides general insights that should be useful to the design of ACS inhibitors for both infectious disease indications as well the treatment of human cancers and metabolic diseases.